CXI Healthcare Technology Group Limited

CXI Healthcare Technology Group Limited

KKRX:900120
2,805.00
KRW
-90.00
(-3.11%)
65.91BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
157,485.29
165,520.71
172,704.22
143,130.05
65,183.71
65,821.25
58,592.6
28,727.8
47,187.73
42,371.45
21,881.31
13,718.88
- -
- -
Basic EPS, GAAP
35,999.99
36,761.91
39,904.76
25,200
350
-33,500.01
-32,000.01
-44,600.01
2,300
2,500
2,300
5,800
- -
- -
Free Cash Flow per Basic Share
40,457.68
41,645.86
51,396.16
28,323.14
24,141.71
-26,024.71
-26,326.59
-49,848.91
-88,501.25
15,037.67
9,653.97
8,629.31
- -
- -
Dividend per Share
3,184.44
- -
- -
- -
3.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
232,345.06
225,174.46
267,641.96
289,830.82
266,848.6
237,051.1
202,671.23
160,061.09
159,363.44
170,312.18
119,674.78
83,463.39
- -
76,791.89
Tangible Book Value per Share
232,345.06
225,174.46
267,641.96
289,830.82
266,848.6
237,051.1
202,606.59
159,995.84
159,299.68
170,245.51
119,674.71
83,463.36
- -
76,791.89
Basic Weighted Avg Shares
2
2
2
2
2
2
2
2
2
2
3
5
1
5
Sales/Revenue/Turnover
264,664
286,376
317,895
297,600
146,319
145,264
129,309
63,406
104,593
101,376
71,617
69,420
- -
- -
Operating Margin (%)
33.04
32.02
31.71
23.69
2.08
-52.66
-56.37
-97.7
4.33
6.21
9.96
27.18
- -
- -
Depreciation Expense
1,449
1,606
2,040
2,139
1,842
1,710
1,380
13,956
18,669
25,713
23,980
24,642
- -
- -
Net Income, GAAP
60,500
63,604
73,452
52,396
786
-73,933
-70,621
-98,437
5,098
5,981
7,528
29,349
- -
- -
Effective Tax Rate (%)
28.12
28.27
26.35
27.03
84.48
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
22.86
22.21
23.11
17.61
0.54
-50.9
-54.61
-155.25
4.87
5.9
10.51
42.28
- -
- -
Working Capital
311,267
340,821
438,055
455,465
455,497
402,659
341,361
222,109
50,716
91,127
118,505
184,556
- -
54,221
LT Debt
54,246
34,384
40,062
- -
- -
- -
- -
- -
226
295
731
157
- -
731
Total Equity
390,340
415,052
537,022
609,515
589,225
523,430
447,547
353,291
371,946
418,839
412,447
481,137
- -
573,553
Return on Invested Capital (%)
15.11
14.51
14.3
8.6
0.08
- -
- -
- -
1.25
1.59
1.72
4.22
- -
- -
Return on Capital (%)
14.84
14.97
14.84
9.02
0.13
- -
- -
- -
1.41
1.52
1.81
6.56
- -
- -
Return on Common Equity (%)
17.04
15.79
15.43
9.14
0.13
-13.29
-14.55
-24.58
1.41
1.51
1.81
6.57
- -
- -

Capital Structure

KRW

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
89
94
101
LT Borrowings
452
585
626
LT Finance Leases
111
107
105
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
7
Market Capitalization
91,977
79,343
65,913

Working Capital

KRW

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
238,875
123,902
55,178
Cash, Cash Equivalents & STI
222,170
116,124
47,082
Accounts Receivable, Net
16,656
7,762
8,077
Inventories
- -
- -
- -
Total Current Liabilities
1,977
1,552
957
Payables & Accruals
- -
- -
- -
ST Debt
89
94
101
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20,205
10,386
12,887
26,058
69,420
2025
18,204
9,176
10,371
- -
- -
2026
16,305
7,375
7,518
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,898.99
-250
450
18,311
5,800
2025
10,400
-3,850
-2,900
- -
- -
2026
775
-595
-405
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jin Sheng Lin
Full Time Employees
26
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
George Town Cayman Islands
IPO Date
Mar 31, 2010
Business
CXI Healthcare Technology Group Limited operates as an investment holding company that manufactures, processes, distributes, and markets traditional Chinese medicine (TCM)-based health foods, functional dietary supplements, raw botanical ingredients, and personal care products. The company operates through several core business divisions: Health Food Products, Raw Material Trading, Tea Products, and Cosmetics and Personal Care. Its comprehensive product portfolio includes TCM-based nutritional supplements in various delivery formats, such as Cordyceps Sinensis capsules, lingzhi mushroom formulations, dietary tablets, concentrated herbal granules, and oral functional tonics marketed under proprietary brands including Wellspring of Life and Yuan Kang; processed teas and loose-leaf products, including specialty Jiang tea, oolong tea, and green tea varieties; wholesale raw botanical materials and active herbal ingredients for commercial clients; and functional skincare and cosmetic products, including hydrating sunscreens, facial serums, and anti-aging topicals under the Kimparis Ellabie line. CXI Healthcare Technology Group distributes its offerings across the People's Republic of China and export markets through a nationwide distribution network, retail pharmacy chains, authorized specialty dealers, and major domestic and cross-border e-commerce platforms such as Tmall Global, JD.com, and Douyin. Founded in 2009 and listed on the KOSDAQ market of the Korea Exchange, the company is headquartered in Grand Cayman, Cayman Islands, and conducts its primary manufacturing, research, and operating activities through Chinese operating subsidiaries, including Fujian Jinshan Da Dao Health Technology Group Co., Ltd. and Fujian Wellspring of Life Bioengineering Co., Ltd. In recent developments, the company officially changed its corporate name from CKH Food & Health Limited to CXI Healthcare Technology Group Limited in October 2023 to reflect a strategic pivot toward integrated healthcare solutions and biotechnology. The company has expanded its multi-channel digital retail strategy via live-commerce streaming, broadened its personal care portfolio, and established research and technological partnerships with research institutes, including affiliates of the Chinese Academy of Sciences and Xiamen University, to advance TCM product R&D and explore AI-driven health diagnostic support. Additionally, between 2024 and 2026, the company completed multiple private placement equity rounds and capital restructuring initiatives to optimize its balance sheet and fund strategic business expansions.